Advances in engineered particles and the subsequent reduction in the API mass required to achieve a therapeutic dose can lead to a reduction in side effects.
Jon Faulkes
Advertisement
Jon Faulkes, formerly business development manager, formulation development, Aesica Pharmaceuticals
Articles by Jon Faulkes
Advertisement
Latest Updated Articles
Fit for the Lung?Published: September 2nd 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
2
PharmTech Weekly News Roundup – Week of November 3, 2025
3
AAPS PharmSci 360 2025: Trends in Bioanalysis
4
How AI, Machine Learning, and Large Language Models Enhance Bioanalysis
5
